Baird raised the firm’s price target on Quest Diagnostics (DGX) to $229 from $224 and keeps a Neutral rating on the shares. The firm updated its model following Q1 results.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DGX:
- Quest Diagnostics price target raised to $245 from $225 at BofA
- Quest Diagnostics price target raised to $230 from $225 at Barclays
- Quest Diagnostics Lifts Outlook On Strong Earnings Call
- Quest Diagnostics price target raised to $225 from $210 at Evercore ISI
- Quest Diagnostics price target raised to $225 from $220 at Jefferies